Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LINNOVATE: A Phase 1/2 Study of Safety/Efficacy Using LURBINECTEDIN, Combined With IPILIMUMAB, and NIVOLUMAB for Advanced Soft Tissue Sarcomas

NCT05876715 is registered in ClinicalTrials.gov with ERLINDA M GORDON as lead sponsor.

NCT NCT05876715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05876715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LINNOVATE: A Phase 1/2 Study of Safety/Efficacy Using LURBINECTEDIN, Combined With IPILIMUMAB, and NIVOLUMAB for Advanced Soft Tissue Sarcomas
Lead sponsor
ERLINDA M GORDON
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 7, 2023
Completion date
September 30, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft-tissue sarcoma